Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
In patients with compensated cirrhosis caused by MASH, efruxifermin did not significantly reduce fibrosis at 36 weeks. (Funded by Akero Therapeutics; SYMMETRY ClinicalTrials.gov number, NCT05039450.).
Authors
- Kitty Yale (ORCID: https://orcid.org/0000-0002-3813-1626)
- Andrew Cheng (ORCID: https://orcid.org/0000-0002-1121-8051)
- Madhavi Rudraraju
- Mary Eugenia Rinella (ORCID: https://orcid.org/0000-0003-0620-9705)
- Reshma Shringarpure (ORCID: https://orcid.org/0000-0001-5936-0447)
- Mazen Noureddin (ORCID: https://orcid.org/0000-0003-2127-2040)
- Erik J. Tillman (ORCID: https://orcid.org/0000-0003-3599-0297)
- Arian Zari
- Tim Rolph (ORCID: https://orcid.org/0000-0001-5284-6903)
- Cynthia A. Behling (ORCID: https://orcid.org/0000-0001-7016-2636)
- Meena Jain (ORCID: https://orcid.org/0000-0003-2700-2500)
- Naga Chalasani (ORCID: https://orcid.org/0000-0003-4082-3178)
- Brittany de Temple
- Doreen Chan (ORCID: https://orcid.org/0000-0001-9301-6789)
- Mark Burch
- Manuel Rodríguez (ORCID: https://orcid.org/0000-0001-5763-7668)
- Rashmee Patil (ORCID: https://orcid.org/0000-0002-8345-0263)
- Guy Neff
- K. Lucas
Institutions
- University of California San Diego (US)
- University of Chicago (US)
- Lucas Research (US)
- Methodist Hospital (US)
- Pinnacle Clinical Research (US)
- Houston Institute for Clinical Research (US)
- Spero Therapeutics (United States) (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1056/nejmoa2502242
- Citations
- 64
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 86.67